TRex Bio, Inc. Common stock (TRXB) News & EventsTRXBTRex Bio, Inc. Common stock

Retension Pharmaceuticals and TRex Bio Begin Trading

Two new biotech names began trading last week, with Retension Pharmaceuticals and TRex Bio making their market debuts on October 9. Retension enters the public markets with a focus on hypertension and cardiovascular therapies, while TRex Bio centers its work on tissue Treg biology and immunoregulatory medicines.LATEST IPOS AND DIRECT LISTINGS:Retension Pharmaceuticalsopened on October 9 at $10. The clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases priced 3.75M shares at $12.00. The deal size was increased to 3.75M shares of common stock from 3.3M shares and priced in the middle of the $11.00-$13.00 range.TRex Bioopened on October 9 at $13.50. The clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines priced 8.333M shares at $14.00. The deal priced at the low-end of the $14.00-$16.00 range.RECENT SPAC IPOS:Pine Tree Acquisitionopened on October 6 at $10.00. Pine Tree is a Cayman exempt company, formed as a blank check company for the purpose of entering into a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. Maxim is acting as the lead book-running manager for the offering.PERFORMANCE:Prices as of 11 am ET on Monday, October 12 -Retension Pharmaceuticals – up about 2% at $10.74;TRex Bio – fractionally up at $14.06.UPCOMING IPOS:Upcoming IPO and direct listings expected include FireFly Robotics, Anthropic, Nscale, Altera, and Brooks Automation.Clickto see upcoming IPO calendar on TipRanks.FireFly Robotics, which designs and manufactures autonomous, all-electric robotic systems for turf and grounds environments, announced it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed public direct listing of its common stock. The company is not selling any shares and will not receive any proceeds in the direct listing.Anthropicis now planning to hold its IPO in November, which is later than the October listing expected by investors, The Wall Street Journal's Corrie Driebusch, Anissa Gardizy, and Kate Clark, citing people familiar with the matter. The report states that a delayed listing would allow the company to share its Q3 results and show its strong competitive position. Anthropic also intends to meet with investors in the coming days, and the meetings are expected to help the company and its bankers gauge investor appetite for the offering, WSJ noted.Nscale Limitedhas filed with the SEC for an initial public offering of its ordinary shares. The company intends to apply to list its ordinary shares on the New York Stock Exchange under the symbol "NSCL". Goldman Sachs, J.P. Morgan, Morgan Stanley are listed as the lead bookrunners.Alteraannounced that its parent company has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed public offering of its common stock. "The number of shares to be offered and the price range for the proposed offering have not yet been determined. The proposed public offering remains subject to the completion of the SEC review process, as well as market and other conditions," Altera stated. Altera, which provides high-performance, programmable compute and connectivity solutions, is backed by Silver Lake and Intel.Brooks Automationannounced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is expected to take place after the SEC completes its review process, subject to market and other conditions."Opening Day" is The Fly's recurring series of stories on the latest initial public offerings, their performance, and upcoming IPOs.